Your browser doesn't support javascript.
loading
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Maurel, Marine; Howard, Jennifer; Kissling, Esther; Pozo, Francisco; Pérez-Gimeno, Gloria; Buda, Silke; Sève, Noémie; McKenna, Adele; Meijer, Adam; Rodrigues, Ana Paula; Martínez-Baz, Iván; Mlinaric, Ivan; Latorre-Margalef, Neus; Túri, Gergo; Lazar, Mihaela; Mazagatos, Clara; Echeverria, Aitziber; Abela, Stephen; Bourgeois, Marc; Machado, Ausenda; Dürrwald, Ralf; Petrovic, Goranka; Oroszi, Beatrix; Jancoriene, Ligita; Marin, Alexandru; Husa, Petr; Duffy, Roisin; Dijkstra, Frederika; Gallardo García, Virtudes; Goerlitz, Luise; Enouf, Vincent; Bennett, Charlene; Hooiveld, Mariëtte; Guiomar, Raquel; Trobajo-Sanmartín, Camino; Visekruna Vucina, Vesna; Samuelsson Hagey, Tove; Lameiras Azevedo, Ana Sofía; Castilla, Jesús; Xuereb, Gerd; Delaere, Bénédicte; Gómez, Verónica; Tolksdorf, Kristin; Bacci, Sabrina; Nicolay, Nathalie; Kaczmarek, Marlena; Rose, Angela Mc.
Afiliación
  • Maurel M; Epiconcept, Paris, France.
  • Howard J; Epiconcept, Paris, France.
  • Kissling E; Epiconcept, Paris, France.
  • Pozo F; CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Pérez-Gimeno G; National Centre for Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Institute of Health Carlos III, Madrid, Spain.
  • Buda S; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Sève N; CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • McKenna A; Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
  • Meijer A; Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
  • Rodrigues AP; HSE Health Protection Surveillance Centre, Dublin, Ireland.
  • Martínez-Baz I; National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands.
  • Mlinaric I; Epidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Latorre-Margalef N; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
  • Túri G; Croatian Institute of Public Health, Zagreb, Croatia.
  • Lazar M; Public Health Agency of Sweden, Stockholm, Sweden.
  • Mazagatos C; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
  • Echeverria A; Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania.
  • Abela S; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Bourgeois M; CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Machado A; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
  • Dürrwald R; Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.
  • Petrovic G; Department of Infectious Diseases, CHU UCL Namur (site Godinne), Université catholique de Louvain, Yvoir, Belgium.
  • Oroszi B; Epidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Jancoriene L; National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
  • Marin A; Croatian Institute of Public Health, Zagreb, Croatia.
  • Husa P; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
  • Duffy R; Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
  • Dijkstra F; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.
  • Gallardo García V; University Hospital Brno and Masaryk University, Brno, Czechia.
  • Goerlitz L; HSE Health Protection Surveillance Centre, Dublin, Ireland.
  • Enouf V; National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands.
  • Bennett C; Servicio de Vigilancia y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Consejería de Salud y Consumo, Andalucía, Spain.
  • Hooiveld M; Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
  • Guiomar R; Centre National de Référence Virus des Infections Respiratoire (CNR VIR), Institut Pasteur Université Paris Cité, Paris, France.
  • Trobajo-Sanmartín C; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
  • Visekruna Vucina V; Nivel, Utrecht, the Netherlands.
  • Samuelsson Hagey T; Laboratório Nacional Referência Gripe e outros Vírus Respiratórios, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Lameiras Azevedo AS; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
  • Castilla J; Croatian Institute of Public Health, Zagreb, Croatia.
  • Xuereb G; Public Health Agency of Sweden, Stockholm, Sweden.
  • Delaere B; Servicio de vigilancia y control epidemiológico, Subdirección general de Epidemiología y Vigilancia de la Salud, Dirección General de Salud pública, Valencia, Spain.
  • Gómez V; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
  • Tolksdorf K; Department of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta.
  • Bacci S; Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.
  • Nicolay N; Department of Infectious Diseases, CHU UCL Namur (site Godinne), Université catholique de Louvain, Yvoir, Belgium.
  • Kaczmarek M; Epidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Rose AM; Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
Euro Surveill ; 29(8)2024 Feb.
Article en En | MEDLINE | ID: mdl-38390651
ABSTRACT
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2) EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI 41 to 63) and 30% (95% CI -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI 30 to 55) and 14% (95% CI -32 to 43), respectively.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article